Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 20/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652080 | 0.83 | JAK3 (0.47) | JAK3 | |
| SCHEMBL2281069 | 0.81 | JAK3 (0.47) | JAK3 | |
| SCHEMBL12402568 | 0.80 | JAK3 (0.47) | JAK3 | |
| SCHEMBL2344126 | 0.80 | JAK3 (0.49) | JAK3 | |
| SCHEMBL651340 | 0.80 | MAPK1 (0.50) | JAK3 | |
| SCHEMBL27821330 | 0.79 | JAK3 (0.46) | JAK3 | |
| SCHEMBL651335 | 0.79 | JAK3 (0.46) | JAK3 | |
| SCHEMBL12450334 | 0.78 | JAK3 (0.60) | JAK3 | |
| SCHEMBL2344123 | 0.78 | JAK3 (0.50) | JAK3 | |
| SCHEMBL650562 | 0.78 | JAK3 (0.47) | JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119636-B2 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2012-02-21 | — | — | US | claimed |
| US-8119685-B2 | Disubstituted aniline compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | claimed |
| EP-2247593-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | claimed |
| EP-2247593-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-10 | — | — | EP | claimed |
| US-20090221669-A1 | Disubstituted Aniline Compounds | MERCK SHARP & DOHME LLC | 2009-09-03 | — | — | US | claimed |
| WO-2009106444-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | claimed |
| US-20090215785-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | claimed |
| EP-2013196-A2 | DISUBSTITUTED ANILINE COMPOUNDS | Merck & Co., Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2007127137-A2 | DISUBSTITUTED ANILINE COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | claimed |
| US-8119636-B2 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119636-B2 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119636-B2 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119685-B2 | Disubstituted aniline compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2247592-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215785-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215785-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215785-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK2 | JAK3 7/4885 |
| US-20090221669-A1 | Disubstituted Aniline Compounds | TXNRD2, BRDT, HDAC1 | JAK3 2879/4885 |
| US-20090215785-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK2 | JAK3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.